Novel piperazine core compound induces death in human liver cancer cells: possible pharmacological properties

Nima Samie¹, Sekaran Muniandy², M. S. Kanthimathi²,³, Batoul Sadat Haerian¹ & Raja Elina Raja Azudin⁴

The current study evaluates the cytotoxic mechanism of a novel piperazine derivate designated as PCC against human liver cancer cells. In this context, human liver cancer cell lines, SNU-475 and 243, human monocyte/macrophage cell line, CRL-9855, and human B lymphocyte cell line, CCL-156, were used to determine the IC₅₀ of PCC using the standard MTT assay. PCC displayed a strong suppressive effect on SNU-475 and SNU-423 cells with an IC₅₀ value of 6.98 ± 0.11 μg/ml and 7.76 ± 0.45 μg/ml respectively, after 24 h of treatment. Significant dipping in the mitochondrial membrane potential and elevation in the released of cytochrome c from the mitochondria indicated the induction of the intrinsic apoptosis pathway by PCC. Activation of this pathway was further evidenced by significant activation of caspase 3/7 and 9. PCC was also shown to activate the extrinsic pathways of apoptosis via activation of caspase-8 which is linked to the suppression of NF-κB translocation to the nucleus. Cell cycle arrest in the G1 phase was confirmed by flow cytometry and up-regulation of glutathione reductase expression was quantified by qPCR. This study suggests that PCC is a simultaneous inducer of intrinsic and extrinsic pathways of apoptosis in liver cancer cell lines.

Liver cancer is the sixth most frequent cause of cancer deaths worldwide and hepatocellular carcinoma is the most common form of liver cancer in adults¹. Cancer is initiated by turning normal cells into tumors by environmental factors such as carcinogens, viruses, chemicals, and radiation as well as by genetic conditions such as germline mutations leading to malignant growth, and invasion and metastasis. Despite the significant progress in diagnosis of liver cancer and using a combination of different modalities, including surgery, chemotherapy, and radiotherapy, remission, relapse, and metastasis are still more frequent than other cancers and the five-year relative survival rate is approximately only 15%². Failure of programmed cell death is a key contributor to both development of cancer and responsiveness to drugs³. Apoptotic pathways are regulated by a number of gene families which finally lead to the phagocytosis of cells by adjacent cells. Central roles are played by death receptors (extrinsic) and mitochondrial (intrinsic) pathways⁴. Although chemotherapy-induced apoptosis is the main approach of numerous anti-cancer therapies, many drugs have been implicated in the emergence of treatment resistance and side effects⁵. Discovery of potent drugs targeting apoptosis signal transduction are warranted to ameliorate clinical consequences in cancer therapy⁶. Piperazines are nitrogen containing heterocyclic compounds and constitute the functional group in several drug backbones which enable them to display a broad range of biological activities such as oxidation and anti-inflammation⁷,⁸. These agents possess a flexible binding feature with a general binding motif which offers potent and selective ligands for a variety of biological targets⁹. Furthermore, interaction with DNA is another outstanding feature of a compound containing piperazine substituents¹⁰. On the basis of these properties, piperazines have been recently used as anticancer¹¹,¹², antifungal¹³, antibacterial and antimalarial agents¹⁴. Effective anti-proliferative activity against colon and breast cancer and leukemia has been
**Table 1. MTT cell proliferation assay for 24, 48 and 72 h on normal and cancer cells.**

| Time (h) | SNU-475 | SNU-423 | THLE-3 | CRL-9855 | CCL-156 |
|----------|---------|---------|--------|----------|---------|
| 24       | 6.98 ± 0.11 | 7.76 ± 0.45 | 48.63 ± 0.12 | 53.12 ± 0.08 | 55.35 ± 0.86 |
| 48       | 6.52 ± 0.23 | 7.42 ± 0.13 | 48.52 ± 0.24 | 52.76 ± 1.76 | 54.42 ± 1.34 |
| 72       | 6.12 ± 0.19 | 7.21 ± 0.25 | 48.39 ± 0.43 | 52.12 ± 0.54 | 54.15 ± 0.93 |

| IC50 (μg/ml) of 5-fluorouracil (5-FU) |
|-------------------------------------|
| 24       | 1.14 ± 0.02 | 1.25 ± 0.06 | 1.37 ± 0.15 | 46.11 ± 0.23 | 44.23 ± 0.56 |

exhibited by piperazine analogues\(^{15}\). Piperazines are interestingly more potent and active than the taxane family, sorafenib, cisplatin and doxorubicin, which are widely prescribed chemotherapeutic agents against different tumors\(^{16}\). Direct induction of apoptosis is a prominent trait of piperazines in the destruction of tumor cells, suggesting this compound as an anticancer drug candidate. The aim of this study was to evaluate the cytotoxic properties of \((2, 4\text{-Dihydroxy-cyclohexyl})\-[4-(3, 5\text{-dihydroxy-cyclohexyl})\text{-piperazin-1-yl}]-methanone designated as PCC against human liver cancer cells. We determined the potency of PCC in the induction of apoptosis.

**Results**

**Purification grade of PCC.** The TLC-system ensured a chromatographic separation of PCC following hydrolysis in HCl. The limit of detection (LOD) for PCC was found to be 1 μg for detection in UV-light at 254 nm. A mixture of acetonitrile in phosphate buffer, pH = 2, was used to optimize the chromatographic separation of PCC from its degradation products to ensure adequate characteristics, such as resolution and a short time of analysis. Among the various contents of acetonitrile (20–70%), a 50% content was finally chosen for the determination of PCC and a 30% content of acetonitrile for purity assay and the kinetic analysis of degradation products. The presence of acetonitrile in the mobile phase showed sharp symmetrical peaks of PCC. The presence of phosphate buffer in the chromatographic solvent allowed a distinct separation of PCC. The retention time was not longer than ca. 2.6 min for internal standard and ca. 5.0 min for in mobile phase A or not longer than 5 min, ca. 8.0 min and 15.0 min in mobile phase B. To establish the intermediate precision, another analyst prepared and determined PCC in three solutions of different concentrations. The RSDs ≤ 1.4% are satisfactory. The detection limit depends on two parameters, such as the composition of the mobile phase and the detection mode, in this case UV detection. In this study the detection limit for PCC was approximately 0.53 μg/ml and its limit of quantification (LOQ) was 1.60 mg/ml. In addition, the HPLC-MS analysis revealed that (M + H)\(^{+}\) peak was observed at the value m/z = 395 (Supplementary Figure 1).

**Cytotoxic effect of PCC on proliferation of cancer cells.** The anti-cancer effect of PCC was evaluated on human liver cancer cells, SNU-475 and SNU-423, human liver cell line, THLE-3, human monocyte/macrophage cell line, CRL-9855, and human B lymphocyte cell line, CCL-156, by triplicate MTT assays. IC\(_{50}\) values for the compound and standard on cell lines tested in this study are shown in Table 1. PCC displayed a high inhibitory effect towards both cancer cells after 24 h. The IC\(_{50}\) of PCC was 6.98 ± 0.11 μg/ml and 7.76 ± 0.45 μg/ml against SNU-475 and SNU-423, respectively, as compared with the standard (1.14 ± 0.02 μg/ml), while the IC\(_{50}\) for PCC in normal liver cells, normal monocyte/macrophage cells and B lymphocyte was calculated as 48.63 ± 0.12 μg/ml, 53.12 ± 0.08 μg/ml and 50.35 ± 0.86 μg/ml respectively.

**PCC induced G1 cell cycle arrest.** Development of cancer is due to dysfunction in the regulation of the cell cycle that appears in over-proliferation of cells, although cancer progression can be strongly limited by conquest of the cell cycle. Hence, the effect of 6.25 μg/ml PCC on cell cycle arrest was investigated. The BrdU and phospho-histone H3 staining of SNU-475 and SNU-423 cells treated with PCC showed that cell cycle arrest at the G1 phase did not occur (Fig. 1). However, cellular arrest in the G1 phase was detected by using flow cytometry (Fig. 2).

**PCC enhanced cytochrome c release and membrane permeability but reduced mitochondrial membrane potential.** Because of the cytotoxic effect of PCC on SNU-475 and SNU-423 cells, permeability of the membrane was higher than in the control suggesting sustained apoptotic activity in these cells (Fig. 3A,B). Loss of mitochondrial membrane potential (MMP) was evidenced as a conceivable mechanism for cell death using MMP dye. The cytoplasm of control cells was stained more intensely than the cells treated with PCC (Fig. 3A). Both SNU-475 and SNU-423 cells treated with PCC for 24 h exhibited a dose-dependent reduction of MMP fluorescence intensity, as a result of collapsed MMP (Fig. 3A,B). The fluorescence intensity in the cytosol of SNU-475 and SNU-423 cells treated with PCC was less than control cells suggesting the release of mitochondrial cytochrome c (Fig. 3B).

**PCC induced cytoskeletal rearrangement and nuclear fragmentation.** SNU-475 and SNU-423 cells treated with PCC were examined for cytoskeletal and nuclear morphological alteration by phalloidin and Hoechst 33342 staining. F-actin was stained at the peripheral membrane evidencing the cell shrinkage (Fig. 4). In addition, nuclear fragmentation and condensation were indicated at the concentrations of 6.25 μg/ml of PCC in 24 h (Fig. 5). Additionally, apoptotic chromatin changes increased nuclear intensity suggesting induction of apoptosis by PCC in these cells.
PCC induced membrane blebbing and nuclear condensation. After 24 h treatment of SNU-475, and SNU-423 cells with 6.25μg/ml of PCC, the apoptotic features were analyzed by fluorescence microscopy. Normal nuclear structure in control cells was displayed as green fluorescence, whereas bright green fluorescence was shown in early apoptotic cells, caused by interposition of acridine orange with the fragmented DNA. Nuclear chromatin pucker and membrane zeiosis, as moderate apoptotic features, were detected after 24 and 48 h. Binding
Detection of apoptosis. Cells were pre-treated with cell membrane permeable calcium chelator EGTA/AM (25 μM) for 1 hour followed by addition of NTC (6.0 μM) for 24 hours. Cells were stained with Annexin V FITC and PI then subjected to flow cytometry analysis. Our data indicates that apoptosis induction by NTC occurred even in the presence of the calcium chelator (Fig. 7). This finding suggests that NTC initiates caspase 8 activation and apoptosis independent from calcium signaling.

PCC enhanced reactive oxygen species production. Following treatment of SNU-475, and SNU-423 cells by PCC for 24 h, ROS production was detected by staining the live cells with DHE. Following rapid oxidation of DHE and production of DCF by ROS, the fluorescence intensity in the cells was quantified by Radiance.
2100 confocal microscope (Bio-Rad, Hercules, CA, USA). The cellular DCF fluorescence levels were remarkably increased in a dose-dependent manner (Fig. 8).

**PCC induced release of lactate dehydrogenase.** Lactate dehydrogenase (LDH) is a cytosolic enzyme and serves as a biomarker for cellular cytotoxicity, loss of membrane integrity and cytolysis. PCC significantly induced release of this enzyme at a concentration of 6.25 μg/ml after 24 h showing the potential cytotoxic effect of PCC on cancer cell lines (Fig. 9).

**PCC mediated NF-κB translocation.** A substantial suppressive effect against TNF-α-stimulated translocation of NF-κB in the SNU-475 and SNU-423 cells was identified at a PCC concentration of 6.25 μg/ml (Fig. 10). Non-stimulated states distinguished by the high NF-κB fluorescence intensity in the cytoplasm of normal cells. High fluorescence intensity was observed in the nucleus of cancer cells. PCC stimulates apoptosis in these cells by activating TNF-α which translocates NF-κB and gradually reduces the fluorescence intensity in the cytoplasm.

**PCC upregulated expression of glutathione reductase.** Real time profiler qPCR-array was used to identify the expression of the genes involved in the cellular stress response in PCC-treated SNU-475 an SNU-423
cells. In this method, 84 human genes involved in oxidative stress and antioxidant defence, the antioxidant peroxiredoxin (PRDX) family and redox control were examined. Results showed that the anti-oxidant related and oxidative stress genes were differentially expressed in the cells in response to PCC. Interestingly, glutathione reductase was noticeably up-regulated by more than 80 fold in SNU-423 and more than 100 fold in SNU-475 as compared with normal cells ($P < 0.05$). These findings were validated by qPCR.

**PCC induced caspase 3/7, 8 and 9.** The bioluminescent intensity of caspase 3/7, 8 and 9 activities of cancer and normal cells was measured at 6, 12, 18, 24, 30, 36 and 42 h time points after PCC treatment. A significant increase of caspase 3/7, 8 and 9 activities was detected after 18 and 24 h of PCC exposure in the cancer cells (Fig. 11). The maximum activity of caspase 9 was observed in both PCC-treated cancer cell lines after 18 h (4.8 fold for SNU-423 and 5.0 fold for SNU-475), whereas after 24 h of PCC exposure, the caspase 3/7 and 8 activities were increased to a peak in both cancer cells and then gradually decreased at the later time points. This finding
suggests that PCC can induce apoptosis in the liver cancer cells through activation of caspase 9 and 8. In addition, the activity of caspase 3/7, 8 and 9 were inhibited by the caspase inhibitor, Z-VAD-FMK (10 μM), in the presence of PCC (6.25 μg/ml).

Western blot analysis disclosed a dose-dependent reduction in the expression level of Bcl-2 (26 KDa) and Bcl-xL (30 KDa) in PCC treated SNU-475 and SNU-423 cells. In both liver cancer cell lines, the level of Bcl-2 and Bcl-xL were substantially altered at 6.25 μg/ml PCC with further down-regulation observed at 12.5 and 25 μg/ml (Fig. 12). In addition, upregulation of p53 (53 KDa) and Bax (23 KDa), cleavage of Bid (22 KDa) to its truncated form (15 kDa) as well as cleavage of caspase-7 (20 KDa), 8 (43 KDa), and 9 (37 KDa) were evident in both cell lines (Fig. 12). Cleavage of caspase 3 subunits including the 17 and 11 kDa subunits, was identified in PCC-treated cancer cells, whereas, cleavage was not detected in normal cells with a similar dosage of treatment. This finding suggests that PCC induces apoptosis through both mitochondrial and extrinsic pathways. PCC also modulates binding of truncated Bid to Bax resulting in the release of cytochrome c from mitochondria.

**Evaluation of acute toxicity.** SD female rats were treated with a single dose of PCC (200 mg/kg). All animals survived the treatment period after 14 days. No physical or abnormal changes was observed in the mucus membrane, eyes, skin, fur, salivation, tremors, behaviour and sleep patterns. Biochemical analysis of liver and
kidney were reported normal (Table 2). No differences were observed in kidney and liver tissue histopathology analysis of PCC-treated rats compared to the normal control group (Fig. 13).

Discussion
The ability of malignant cells to evade apoptosis is a hallmark of cancer. Thus, a comprehensive understanding of apoptotic signaling pathways is mandatory for discovery of target selective therapeutic drugs. Through investigation of the properties of PCC as a new derivative of piperazine in the current study, we found that this agent is potentially cytotoxic against liver cancer cells. In particular, PCC can simultaneously induce both extrinsic and intrinsic apoptotic signaling pathways in these cells. PCC showed a selective activity against cancer cells with no effect on normal cells. This feature can be considered as a prominent property of this compound in cancer treatment. Our findings provide molecular evidence for potential cytotoxic properties of PCC in the liver cancer cells by its stimulation of both extrinsic and intrinsic apoptotic signaling pathways.

Apoptosis consists of morphological and biochemical changes. Following a death signal, morphological events initiated by cell shrinkage and chromatin condensation proceed to membrane blebbing and nuclear fragmentation and finally end with apoptotic body formation. To address whether PCC induces cytological alterations in the liver cancer cell lines, we monitored the cell membrane, LDH and cytochrome c release, ROS production, mitochondrial membrane potential, cytoskeleton, nuclear fragmentation and NF-κB translocation in PCC treated cells. Results showed that PCC can stimulate cytoskeletal shrinkage-related reorganization. This compound substantially damages membrane integrity at a concentration of 6.25 μg/ml, leading to LDH release from the cells as a marker of cytotoxicity (Fig. 9). Analysis of membrane blebbing and chromatin condensation by using AO/PI staining revealed the morphological changes relevant to the apoptotic event (Fig 5 and 6)17. By increasing the period of the cell exposure to PCC from 24 to 72 h, modifications of the early to the late stage of apoptotic events appeared, suggesting that prolonged treatment of cancer cells with PCC can activate necrosis in these cells18–20. Cell cycle distribution was furthered investigated to support the occurrence of apoptosis in the cancer cells through BrdU and Phospho-Histone H3 staining18,20. However, neither BrdU attachment nor H3 staining in the mitotic stage was identified, indicating that there was no significant difference in the number of cells in the S/M phases. Based on flow cytometric analysis, the cells were observed to be arrested at the G1 or G2 phases. This finding confirms that cell death is triggered by apoptosis21,22. Mitochondria are the main source of ROS which regulate survival or death of cells. Our data show an extensive enhancement in the ROS levels in the PCC (6.25 μg/ml) treated cells. PCC stimulates ROS production through upregulation of GR. The enzyme, GR, as an oxidative stress indicator, plays an important role in the suppression of reactive oxygen species and in antioxidant function. Enhanced ROS production by PCC could stimulate de novo synthesis of GR23.

Disproportionate ROS production diminishes mitochondrial membrane potential leading to cytochrome c release from mitochondria into the cytoplasm. An increased mitochondrial cytochrome c level in the cytoplasm is a key initiating signal for induction of the intrinsic apoptosis pathway by PCC (Fig. 3A)24,25. Thus, PCC can be
seen as a potential inducer of morphological modifications downstream of apoptotic molecular events in the liver cancer cells associated with its cytotoxic potential.

Piperazines (1, 4-diazacyclohexane) are an extensive group of chemical compounds, containing a core functional group with important pharmacological properties. They consist of a six-membered ring containing two nitrogen atoms at opposite positions in the ring. A large number of piperazine compounds have anthelmintic action. They are usually used as anti-helmintic against common roundworms such as ascariasis and pinworms (enterobiasis; oxyuriasis). Their mode of action is generally by paralysing parasites, which allows the host body to easily remove or expel the invading organism. Based on the literature, unsubstituted piperazine do not show anti-cancer effect however, but when they are incorporated into another molecule or are used as a derivate, some of them tend to show anti-cancer activity based on the compound's structure. PCC is a piperazine derivate which has potential cytotoxic effect toward liver cancer cell lines. Nevertheless, there is little data showing that piperazine compounds can induce apoptosis pathways associated with their cytotoxic properties. Recent studies have demonstrated the cytotoxic effect of some piperazine derivatives such as β-elemene piperazine, 1,4-bis-(4-(1H-benzo[d]imidazol-2-yl)-phenyl) piperazine and chloroalkyl piperazine and 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl) purine in cancer cells. However, only the extrinsic pathway of apoptosis is activated by these compounds whereas, PCC simultaneously activates both intrinsic and extrinsic pathways of apoptosis. To further support the role of PCC as a novel piperazine derivative with pro-apoptotic properties, we analyzed the apoptotic pathways in the liver cancer cell lines. Results showed that PCC enhanced the release of mitochondrial cytochrome c which activated caspase 9 by 4.8–5.0 fold in both liver cancer cells. Interestingly, activated caspase-8 is also increased by about 5.0 fold in both cancer cell lines, suggesting that PCC-induced apoptosis is mediated by more than one pathway. Following cell excitation, calcium ions are released from mitochondria to regulate several cellular processes such as apoptosis. Therefore, prolonged elevation of cytosolic calcium ions causes cell death. In addition, mitochondrial calcium ion uptake alters the mitochondrial permeability which switches on the apoptosis event in response to the stress. Increase of calcium ion levels occurs at both the early and late stages of apoptosis. Hence, intracellular calcium ion elevation causes cell death through apoptosis pathways. On the basis of the absence of cytosolic free calcium evaluated by using a calcium chelator (EGTA/AM) and flow cytometry analysis of Annexin-V in the PCC treated cells, an increase in the number of

Figure 12. Western blot analysis of cancer and normal cell lines. Cells were treated with 3.12 and 6.25 μg/ml of PCC for 24 h. Proteins were transferred to a membrane and followed by probing with antibodies. Normalization of band densities of treated samples were accomplished based on the control. The results represent significant increase in the expression level of caspase 3, 7, 8, 9, p53, Bax and conversion of Bid to its truncated form, where as decrease in Bcl-2 and Bcl-xL levels.
cells was detected (Fig. 7). Therefore, caspase 8 has been activated by PCC independent of intracellular calcium concentrations.

In liver cancer, development of resistance against various therapeutic interventions, such as chemotherapy has been linked to the expression of Bcl-2 and Bcl-xL.37-39 Bcl-2 is an anti-apoptotic mediator that is expressed in different cancer types and serves as a checkpoint in execution of the caspase cascade and mitochondrial dysfunction.24,25,40 Vis-à-vis, Bcl-xL blocks cell death through regulation of mitochondrial homeostasis.25,32 Furthermore, the tumor suppressor P53, an apoptosis mediator in numerous cells, activates by DNA damage and triggers apoptosis to eliminate permanently damaged cells.41 Dysfunction or down-regulation of p53 may induce tumor progression and resistance to chemotherapy.42 Our experimental data show that PCC reduces the levels of Bcl-2 and Bcl-xL, but increases p53 concentration in the PCC-treated liver cancer cells. Cytotoxic drugs can mediate cleavage of Bid through activation of caspase 8.37,38 In the absence of interaction between ligand and death domain adaptor protein, some drugs may activate caspase-8.39 Following the conversion of Bid to its truncated form (tBid), mitochondrial cytochrome c is released into the cytoplasm to activate Bax.43 In this study, the process of cell death was associated with upregulation of Bax and caspase-8/Bid pathway in PCC treated cells.44,45 In addition, we showed that the anticancer potential of PCC is via blocking the NF-κB signaling pathways. Targeting the NF-κB signaling pathway by drugs has been considered as novel chemotherapeutic objectives in cancer therapy.5,46,47 Evidence showed a linkage between anticancer drug resistance and enhanced activity of the NF-κB pathway.46 NF-κB antagonists inhibit binding of this molecule to DNA resulting in suppression of cell proliferation. There are numerous NF-κB inhibitors available in the market that inhibit the translocation of NF-κB to the nucleus. Based on our results, PCC can be considered as antagonist/inhibitor of the NF-κB pathway because PCC

| Group            | GGT (IU/l) | AST (IU/l) | ALT (IU/l) | AP (IU/l) | Globulin (g/l) | Albumin (g/l) | Total protein (g/l) | Na (mmol/l) | K (mmol/l) | Cl (mmol/l) | CO₂ (mmol/l) | Urea (mmol/l) |
|------------------|------------|------------|------------|-----------|----------------|---------------|---------------------|-------------|-----------|-------------|--------------|---------------|
| Vehicle          | 3.7 ± 0.34 | 253 ± 6.65 | 58.9 ± 4.87| 85.3 ± 4.6| 52.6 ± 0.67    | 13.6 ± 0.76   | 53 ± 1.8            | 147 ± 0.65  | 8.2 ± 0.11 | 105 ± 0.26  | 21.7 ± 0.54  | 6.5 ± 0.76    |
| PCC (200 mg/kg)  | 3.8 ± 0.76 | 257 ± 4.34 | 60.6 ± 2.45| 88.6 ± 1.56| 51.4 ± 0.11    | 10.8 ± 0.16   | 52 ± 0.76            | 151 ± 0.32  | 9.1 ± 0.65 | 109 ± 0.34  | 23.4 ± 0.14  | 7.1 ± 0.24    |

Table 2. Effects of 200 mg/kg PCC on the liver and renal function test. Values are expressed as the means ± S.E.M. There were no statistically significant differences between the measurements of different groups. Significance was set at P < 0.05.
inhibits nuclear translocation of NF-κB, resulting in cell death. Hence, we conclude that other NF-κB inhibitors may not have any influence on the biological effect of PCC, though they could act in synergy with PCC. In summary, among all mechanisms found in this study, simultaneous initiation of the intrinsic and extrinsic pathways of apoptosis via series of caspase activity, cell cycle arrest, down-regulation of Bcl-2 and Bcl-xl, up-regulation of p33 and Bax and inhibiting the NF-κB pathway are the most critical effects of PCC on liver cancer cells.

Conclusion
Evaluation of the cytotoxic properties of PCC in the current study suggests that this compound has potential as an anticancer agent against liver cancer cells. PCC simultaneously induces both intrinsic and extrinsic apoptosis pathways, and hence, can be nominated as a potential anti-cancer agent for future in vivo studies.

Methods
Synthesis procedure. Using tert-Butyl piperazine-1-carboxylate, a Buchwald coupling was performed. Deprotection of the carbamate was achieved using 20% HCl in methanol. Subsequent amidation using triethylamine and various acyl chlorides yielded the final compounds that were tested after purification and structure validation using NMR. Yield: 1.9 g, 85%. M.p.:138–140°C, Anal. Calc. For C_{30}H_{26}N_{4}O_{2} (320.48): C, 74.98; H, 6.29; N, 8.74. Found: C, 75.02; H, 6.45; N, 8.66. 1H NMR (400 MHz, DMSO-d_{6}, δ ppm): 1.59 (6H, s, CH{eq}_3{eq}); 7.07 (1H, m, Ar-H); 7.18–7.22 (3H, m, Ar-H); 7.32 (1H, t, Ar-H); 7.41 (1H, d, Ar-H); 7.46 (1H, d, Ar-H); 7.76 (1H, d, Ar-H); 8.69 (1H, d, J = 12.8 Hz, HCN); 9.43 (s, 1H, HCO); 14.31 (1H, d, J = 12.8 Hz, NH). 13C NMR (100 MHz, DMSO-d_{6}, δ ppm): 22.17, 54.44, 56.74, 109.31, 112.50, 115.39, 118.84, 121.66, 121.68, 125.56, 126.02, 127.95, 128.77, 146.12, 149.33, 151.52, 155.32, 183.50, 188.77 (Supplementary Figure 2A,B).

Purification procedure. The spectrophotometric analysis for PCC in hydrochloric acid (0.01 mol/l) was performed using a UV/VIS Lambda 20 (Perkin Elmer) spectrophotometer (Supplementary Figure 3). The specific absorption coefficient and the molar absorbency index for PCC were calculated based on the Lambert-Beer equation (Table 3). The solutions of PCC were prepared over a concentration range from 0.00098% to 0.00141%. The course of hydrolysis in an acidic medium (at HCl 0.1 mol/l) was followed by the TLC method using plastic sheets 20 × 20 cm with silica gel (0.2 mm) 60 F 254 (Merck). A thin-layer chromatographic tank with a flat bottom of transparent glass of size 27.5 × 27.5 × 7.5 cm was found to be suitable. The chromatographic solvent consisted of a mixture of butanol- acetic acid (1.05 mol/l)-water (80: 12: 30). The spectrophotometric analysis for PCC in hydrochloric acid (0.01 mol/l) was validated using NMR. Yield: 1.9 g, 85%. M.p.:138–140°C, Anal. Calc. For C_{30}H_{26}N_{4}O_{2} (320.48): C, 74.98; H, 6.29; N, 8.74. Found: C, 75.02; H, 6.45; N, 8.66. 1H NMR (400 MHz, DMSO-d_{6}, δ ppm): 1.59 (6H, s, CH{eq}_3{eq}); 7.07 (1H, m, Ar-H); 7.18–7.22 (3H, m, Ar-H); 7.32 (1H, t, Ar-H); 7.41 (1H, d, Ar-H); 7.46 (1H, d, Ar-H); 7.76 (1H, d, Ar-H); 8.69 (1H, d, J = 12.8 Hz, HCN); 9.43 (s, 1H, HCO); 14.31 (1H, d, J = 12.8 Hz, NH). 13C NMR (100 MHz, DMSO-d_{6}, δ ppm): 22.17, 54.44, 56.74, 109.31, 112.50, 115.39, 118.84, 121.66, 121.68, 125.56, 126.02, 127.95, 128.77, 146.12, 149.33, 151.52, 155.32, 183.50, 188.77 (Supplementary Figure 2A,B).

| λ (nm) | SD | SDI | RSD (%) | ε ± Δε |
|-------|----|-----|---------|--------|
| 225   | 11.6 | 4.75 | 1.67 | 275.34 ± 473 |
| 285   | 1.21 | 0.50 | 1.58 | 3037 ± 39 |
| 350   | 1.16 | 0.47 | 0.90 | 5089 ± 39 |

Table 3. Specific absorption coefficients and molar absorbency indexes of PCC in HCl (0.01 mole/l) at maximum absorption wavelengths.

Cell culture. Human liver cell line (THLE-3), cancer cell lines (SNU-475 and SNU-423), normal B lymphocyte (CCL-156) and normal monocyte/macrophage (CRL-9855) were purchased from American Type Culture Collection (ATCC, Manassas, Virginia, USA). SNU-475, SNU-423 and CCL-156 were cultured in Roswell Park Memorial Institute medium (RPMI-1640) supplemented with 10% heat inactivated fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO) and 1% penicillin and streptomycin. THLE-3 was grown in Bronchial Epithelial Cell Growth Medium (BGEM) bulketkitTM (Lonza/Clonetics Corporation, Walkersville, MD 21793) whereas, CRL-9855 was grown in Iscove’s Modified Dulbecco’s Medium (IMDM, ATCC 30-2005, Manassas, Virginia, USA) with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and supplemented with 0.05 mM 2-mercaptoethanol, 0.1 mM hypoxanthine and 0.016 mM thymidine, 90%; fetal bovine serum, 10%. All cell lines were cultured in a humidified incubator with 5% CO₂ at 37°C. All experiments were conducted on cell lines with passage number 1 to 10.
Cell viability assay. The MTT [3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide] assay was carried out to evaluate the anti-proliferative activity of PCC. PCC was originally synthesized as a novel compound by Chemistry and Chemical Engineering Research Centre of Iran (CCERCi, Tehran, Iran) and donated to conduct this study. Briefly, cells were seeded 24 h prior to treatment in a 96-well plate at $7 \times 10^4$ cells/ml. PCC and 5-fluorouracil (standard) were dissolved in DMSO (Sigma Chemical Co., St. Louis, Missouri, USA). After incubation of the plate for 24, 48 and 72 h at 37°C with 5% CO$_2$, 50 μl of MTT solution (2 mg/ml; Sigma) was added to each well. The plates were then incubated for 24 h under the same conditions. To dissolve the purple formazan crystals, 200 μl DMSO was added to each well and incubated for 20 min. Absorbance was subsequently read at 570 nm using a spectrophotometric plate reader (Hidex, Turku, Finland). Experimental data were derived from three independent experiments. The selectivity index was obtained by mean IC50 THLE-3/mean IC50 of SNU-475 or SNU-423.

Immunofluorescence. After 24 h PCC treatment of both cancer and normal cells, 10 μg/ml JC-1 mitochondrial membrane potential dye (eBioscience, San Diego, CA) were added to live cells followed by incubation for 30 min at 37°C. Cells were then fixed in 4% paraformaldehyde, permeabilized by 0.25% Triton X-100, quenched with 50 mM ammonium chloride and blocked with 5% BSA in PBS overnight, followed by probing with 5 μg/ml anti-cytochrome c antibody (Alexa Fluor 488, Abcam Inc., Cambridge, MA, USA) for 1 h. 10 μg/ml DMSO (Phalloidin and 4 μg/ml Hoechst 33342 (Thermo Scientific, Hudson, NH, USA) were added into the staining solution and cells were incubated at room temperature for 20 min. Finally, cells were washed with PBS and coverslips were mounted using polyvinyl alcohol mounting medium (Fluka Analytical, Milan, Italy). Fluorescence was analyzed using the Radiance 2100 confocal microscope (Bio-Rad, Hercules, CA, USA). Noise reduction was attained by Kalman filtering during application and data were analyzed with Data Viewer version 3.0.

Cell cycle analysis using flow cytometry. Briefly, after incubation of the cells with PCC (6.25 μg/ml) for 24, 48 and 72 h, cell were centrifuged at 1800 rpm for 5 min and followed by mixing the cell pellets with 700 ml of cold 90% ethanol and maintaining at 4°C overnight. Cells were washed and suspended in PBS and 25 μl RNase A. 50 ml of propidium iodide (PI) was then added to the fixed cells followed by incubation for 1 h at 37°C. The DNA content of the cells was analyzed using CytoFLEX Flow Cytometer (Beckman Coulter Inc., CA, USA).

Live/dead cell determination. Accurate determination of live/dead nucleated cell concentration in the sample was accomplished by the minor modified version of the method described by Rahman et al.$^{49}$. Propidium iodide (PI) and acridine orange (AO) double staining assay was performed to detect the early and late apoptotic properties of the treated cancer cells according to the standard procedure. Cells were incubated with PCC (6.25 μg/ml) for 24, 48, 72 h and the harvested cells were stained with acridine orange and propidium iodine and observed within 30 min using a UV-fluorescent microscope (Bio-Rad, Hercules, CA, USA).

Quality assay of apoptosis. Cells were treated with cell membrane permeable calcium chelator (EGTA/AM, 25 μM, Life Technologies, Gaithersburg, MD, USA) for a period of 1 h prior to addition of PCC (6.25 μg/ml). After 24 h treatment, cells were harvested, washed twice with PBS, resuspended in Annexin-V binding buffer (BD Biosciences, San Jose, CA, USA) and stained with Annexin-V-FITC (BD) and PI (sigma) according to the manufacturer’s protocol. The fluorescence intensity was then examined using CytoFLEX Flow Cytometer (Beckman Coulter Inc., CA, USA). Annexin-V was used for determination of early and late apoptosis, where as PI was used for distinguishing necrosis and late apoptosis.

Determination of antioxidant potential. Organisms have complex antioxidant systems to protect themselves from oxidative stress; however, excessive oxidative stress can overwhelm the system and cause severe damage. To measure the antioxidant protection potential of PCC over time, the ORAC assay was used. In a black 96-well plate, 6.25 μg/ml of PCC, blank (solvent/PBS) and standard (5-fluorouracil) were added to cells supplemented with fluorescein solution (150 μl) and incubated at 37°C for 5 min. AAPH (25 μl) was then added and fluorescence intensity was assessed at 485 nm (excitation wavelength) and 538 nm (emission wavelength) every 2 min for duration of 2 h. Quantification was carried out by calculating the differences of area under the fluorescence decay curve of the samples and blank.

Detection of ROS production. ROS is produced as byproducts during mitochondrial electron transport and has potential to cause apoptosis. Intracellular reactive oxygen species were measured by using 10 mM dihydroethidium (DHE) stock solution (in methanol) diluted 500-fold in HBSS without serum or other additives to yield a 20 mM working solution. The cells in the black plate were washed twice with HBSS after exposure to PCC following incubation of 100 μl DHE working solution at 37°C for 30 min. Fluorescence intensity of DCF was analyzed using Radiance 2100 confocal microscope (Bio-Rad, Hercules, CA, USA).

LDH release analysis. Quantitative measurement of lactate dehydrogenase (LDH) released into the media from damaged cells as a biomarker for cellular cytotoxicity and cytolsis was carried out according to Wang et al.$^{49}$ with slight modifications. Briefly, cells were treated with different concentrations of compound PCC and Triton X-100 (positive control) for 48 h followed by transfer of the supernatants of untreated and treated cells to a new 96-well plate for LDH activity analysis. 100 μl of LDH reaction solution was then added to each well, followed by incubation at room temperature for 30 min. The absorbance was read at 490 nm using a Tecan Infinite 200 Pro (Tecan, Mannedorf, Switzerland) microplate reader. LDH activity of the cells was assessed by the amount of formazan salt and intensity of red color in treated and untreated samples. Release of LDH level in treated cells was expressed as a percentage of LDH release in the positive control.
Evaluation of NF-κB translocation. Nuclear factor kappa-light-chain-enhancer of activated B cells controls transcription of DNA and is involved in cellular responses to stimuli such as stress, free radicals and chemicals. Cells were treated with (6.25 μg/ml) and stimulated with TNF-α. The Cellomics nuclear factor-kB (NF-κB) activation kit (Thermo Scientific) was used for staining of the cells. The average intensity ratio (200 cells/well) of the nuclear and cytoplasmic NF-κB was measured using cytoplasm to nucleus translocation bio-application software (S50-5001-1, Thermo Scientific).

Evaluation of gene expression in the cells. SNU-475 and SNU0423 cells were treated with PCC (6.25 μg/ml) for 24 h. Total RNA was extracted using RNeasy plus mini kit (Qiagen). Reverse transcription of 1 mg RNA into cDNA was carried out by using RT2 first strand kit (SA Biosciences, Qiagen). TR2 Real Time TM SYBR Green/fluorescein PCR master-mix was then mixed with cDNA and loaded into each of the 96 wells of the 84 genes by qPCR array according to the manufacturer’s protocol (SA Biosciences, Qiagen). Differential expression of the members of antioxidant peroxideroxin (PRDX) family and redox control which are involved in human oxidative and cellular stress were analyzed. Concisely, 12.5 ml master mix, 11.5 ml double distilled water, and 1 ml cDNA was mixed to a final volume of 25 ml PCR mixture and loaded into each well of the 96-well plate. QuantStudio™ 12K Flex Real-Time PCR system consuming ssoFast EvaGreen Supermix (Bio-Rad) was carried out according to the manufacturer’s protocols. Primes were synthesized as GR F5′-AACATCCCAACTGGTGCTTCCAGC-3′, GR R5′-TTGGTAACCTGGTGATACATCGGG-3′, β-actin F5′-GATGACCCAGATCATGTTTGAGACC-3′ and β-actin R5′-AGTCCATACGATGCAGTGTT-3′. Amplification was operated at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. The average expression of five housekeeping genes including β-actin (ACTB), β-2-microglobulin (B2M), hypoxanthine phosphoribosyltransferase 1 (HPRT1), ribosomal protein L13a (RPL13A) gyceraldehyde-3-phosphate dehydrogenase (GAPDH) was considered for normalization of mRNA expression of each gene. The difference in gene expression between piperoxine and untreated control was calculated by RT Profiler qPCR-array data analysis software to measure the fold changes.

Evaluation of mitochondrial and extrinsic apoptotic pathways. Caspases are a family of cysteine proteases that have critical roles in apoptosis. Caspase 9 is involved in the intrinsic, whereas. Caspase 8 is involved in the extrinsic pathway of apoptosis. Caspase 3 interacts with caspase 8 and 9 and plays a central role in the execution phase of the cell apoptosis. Time-dependent evaluation of caspase 3/7, 8 and 9 activities in the presence of PCC (6.25 μg/ml) was performed using assay kits, Caspase-Glo 3/7, 8 and 9 (Promega Corp., Madison, WI, USA) in triplicates on white 96-well plates after 6, 12, 18, 24 and 30 h. Treatment with PCC (6.25 μg/ml) was carried out on a total of 10,000 cells per well and 100 ml of the Caspase-Glo reagent added and incubated at room temperature for 30 min. Cleavage of the aminoluciferin-labeled synthetic tetrapeptide based on the caspase activation, causes apoptotic cells to release the substrate of luciferase enzyme. Activity of caspase was evaluated using Tecan Infinite 200 Pro (Tecan, Mannedorf, Switzerland) microplate reader.

Molecular identification of apoptotic proteins induced by PCC. Apoptotic proteins have a central role in the regulation of programmed cell death via inducing (pro-apoptotic) or inhibiting (anti-apoptotic) apoptosis. 1 × 10⁷ cells/ml were treated with PCC and standard (5-fluorouracil) separately for 24 h. Cells were then aspirated, lyzed and resolved on 10% SDS-polyacrylamide gels followed by transferring of the proteins to PVDF membranes (Milipore) and blocking with 5% nonfat dry milk in PBS-T (0.05% Tween 20) for 1 h at room temperature. Primary antibodies, included Bid (1:1000), caspase-3 (1:1000), caspase-8 (1:1000), anti-β-actin (1:5000), Bax (1:1000) Santa Cruz Biotecnology Inc. (Santa Cruz, CA, USA), Bcl-xL (1:1000), Bcl-2 (1:1000), p53 (1:1000) (Abcam Inc., Cambridge, MA, USA). Secondary antibodies conjugated to horseradish peroxidase were obtained from Kirkegaard & Perry Laboratories Inc. (Gaithersburg, MD, USA). Protein-antibody complexes were detected using Amersham ECL premier Western blotting detection reagent (GE Healthcare, Munich, Germany).

Acute toxicity. The acute toxicity study was conducted according to the OECD protocol[58]. Twelve SD female rats were used for the acute toxicity study to evaluate the toxicity of PCC. All experimental protocols were approved by the ethics committee of the Faculty of Medicine, University of Malaya, Malaysia (Ethics reference no. 2015–180804/PHAR/R/BH). The methods were carried out in accordance with the National Academy of Science’s Guide for the Care and Use of Laboratory Animals[51]. Two groups of animals was considered: the normal control group, which received only vehicle (5 ml/kg of 10% Tween–20), and the treated groups, which received a 200 mg/kg of PCC[25]. Prior to the experiment, all mice were fasted for 24 hours. After treatment, the animals were observed for the first 30 minutes and 4–5 times at intervals of 48 hours to discern any signs of abnormality. After 14 days, the animals were sacrificed by an overdose of xylazine and ketamine anesthesia. Blood samples were then collected for serum biochemical examination. In addition, kidney and liver histological analysis was performed using hematoxylin and eosin staining. All values are means of three experiments.

Statistical Analysis. All values are expressed as mean ± S.D. Student’s t-test was used for statistical evaluation of data. A probability value of *p < 0.05 was considered statistically significant.

References
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA: Cancer J Clin. 65, 3–29 (2015).
2. Cancer, I. A. f. R. o. & Organization, W. H. GLOBOCAN: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. (IARC, 2014).
3. Brown, J. M. & Attardi, L. D. The role of apoptosis in cancer development and treatment response. *Nat Rev Cancer*. 5, 231–237 (2005).

4. Thangam, R. *et al*. Activation of intrinsic apoptotic signaling pathway in cancer cells by Cymbopogon citratus polysaccharide fractions. *Carbohydr Polym*. 107, 138–150 (2014).

5. Kranz, D. & Dobbeltstein, M. A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy. *Cell Cycle*. 11, 2053–2054 (2012).

6. Ahmed, W. & Van Etten, R. A. Signal transduction in the chronic leukemias: implications for targeted therapies. *Curr Hematol Malig Rep*. 8, 71–80 (2013).

7. Assif, M. Piperazine and Pyrazine containing molecules and their diverse pharmacological activities. *Int J Adv Sci Res*. 1, 05–11 (2015).

8. Siddiqui, N. *et al*. Antidepressant potential of nitrogen-containing heterocyclic moietyes: An updated review. *J Pharm Bioall Sci*. 3, 194 (2011).

9. Berkheji, M. *et al*. Synthesis of 2-substituted piperezines via direct α-lithiation. *Tetrahedron Lett*. 46, 2369–2371 (2005).

10. Wilson, W. D., Barton, H. J., Tanious, F. A., Kong, S. & Strekowski, L. The interaction with DNA of unfused aromatic systems containing terminal piperazine substituents: Intercalation and groove-binding. *Biophys Chem*. 35, 227–243 (1990).

11. Gillet, R. *et al*. Piperazine derivatives of butyric acid as differentiating agents in human leukemic cells. *Cancer Chemother Pharmacol*. 41, 252–255 (1997).

12. Hulme, C. & Cherrier, M.-P. Novel applications of ethyl glyoxalate with the Ugi MCR. *Tetrahedron Lett*. 40, 5295–5299 (1999).

13. Upadhyaya, R. S. *et al*. Optically active antifungal azoles: synthesis and antifungal activity of (2R, 3S)-2-(2, 4-difluoro)phenyl)-3-(5-(4-aryl-piperazin-1-yl)-ethyl)-triazol-2-yl)-yl-1)-1-[1, 2, 4-triazol-1-yl-butan-2-oil. *Bioorg Med Chem*. 12, 2225–2238 (2004).

14. Chaudhury, P. *et al*. Synthesis and antinociceptive activity of N-alkyl and N-arylpiperazine derivatives. *Bioorg Med Chem*. 14, 1819–1826 (2006).

15. Yoshida, M., Maehara, Y. & Sugimachi, K. MST-16, a novel bis-dioxopiperazine antiangiogenic agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy. *Clin Cancer Res*. 5, 4295–4300 (1999).

16. Hatnapure, G. D. *et al*. Synthesis and biological evaluation of novel piperazine derivatives of flavone as potent anti-inflammatory and antinociceptive agent. *Bioorg Med Chem Lett*. 22, 6385–6390 (2012).

17. Aarts, M. *et al*. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. *Cancer Discov*. 2, 524–539 (2012).

18. Wang, L., Xu, Y., Fu, L., Li Y. & Lou, L. (5R)-5-hydroxytrioxolane (LLTD-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcriptional inhibition. *Cancer Lett*. 324, 75–82 (2012).

19. Tentner, A. R. *et al*. Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. *Mol Syst Biol*. 8, 504 (2012).

20. Gasparri, F., Cappella, P. & Galvani, A. Multimetric pan cell cycle analysis by automated microscopy. *J Biomed Screen*. 11, 586–598 (2006).

21. See, W. L. *et al*. Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced dihydroangiogenesis. *Oncogene*. 29, 1720–1731 (2010).

22. Liu, Y.-I.* et al*. Synthesis, characterization, cytotoxicity, apoptotic inducing activity, cellular uptake, interaction of DNA binding and antioxidant activity of silver(i). *Cryst Eng Comm*. 10, 2524–2534 (2012).

23. Wang, L., Xu, Y., Fu, L., Li Y. & Lou, L. (5R)-5-hydroxytrioxolane (LLTD-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcriptional inhibition. *Cancer Lett*. 324, 75–82 (2012).

24. Elmore, S. Apoptosis: a review of programmed cell death. *Toxicol Pathol*. 35, 495–516 (2007).

25. Hsu, S. C. *et al*. Flexible “piperazine-pyrazine” building blocks: conformational isomerism of “equitorial–axial” sites towards the constructions of silver(i). *Cryst Eng Comm*. 12, 3588 do:10.1039/c001735c (2010).

26. Yu, Z. *et al*. γ-Elmene piperazine derivatives induce apoptosis in human leukemia cells through downregulation of c-FLIP and generation of ROS. *PloS One*. 6, e15843 (2011).

27. Sampson III, J. J., Donkor, I. O., Huang, T. L. & Adunyah, S. E. Novel piperazine induces apoptosis in U937 cells. *Int J Biochem Cell Biol*. 2, 78 (2011).

28. Guo, C.-C., Tong, R.-B. & Li, K.-L. Chloroalkyl piperazine and nitrogen mustard porphyrins: synthesis and anticancer activity. *Bioorg Med Chem*. 12, 2469–2473 (2004).

29. Tuncbilek, M., Bilget Guven, E., Onder, T. & Cetin Atalay, R. Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(4-ribofuranosyl) purine derivatives, which lead to senescence-induced cell death in liver cancer cells. *J Med Chem*. 55, 3058–3065 (2012).

30. Baumgartner, H. K. *et al*. Caspase-8-mediated apoptosis induced by oxidative stress is independent of the intrinsic pathway and dependent on cathepsins. *Am J Physiol Gastrointest Liver Physiol*. 293, G296–G307 (2007).

31. Baliga, B. & Kumar, S. Apaf-1/cytochrome c apoptosis: an essential initiator of caspase activation or just a sideshow? *Cell Death Differ*. 10, 16–18 (2003).

32. Rizzuto, R., Giorgi, C., Romagnoli, A. & Pinton, P. Ca2+ signaling, mitochondria and cell death. *Curr Mol Med*. 8, 119–130 (2008).

33. Krumn, L., Guo, Q. & Mattson, M. P. Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. *J Neurosci Res*. 51, 293–308 (1999).

34. Tombal, B., Demmeade, S. & Isaacs, J. Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis. *Cell calcium*. 25, 19–28 (1999).

35. Lynch, K., Fernandez, G., Pappalaro, A. & Peluso, J. Basic Fibroblast Growth Factor Inhibits Apoptosis of Spontaneously Immortalized Granulosa Cells by Regulating Intracellular Free Calcium Levels through a Protein Kinase Cδ-Dependent Pathway. *Endocrinology*. 141, 4209–4217 (2000).

36. Hyer, M. L. *et al*. Apoptotic activity and mechanism of 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer. *Cancer Res*. 68, 2927–2933 (2008).

37. Friesen, C., Herr, I., Krammer, P. H. & Debatin, K.-M. Involvement of the CD95 (APO–1/Fas) receptor/ligand system in Fas-induced apoptosis and Fas-induced death in lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. *Blood*. 97, 1378–1387 (2001).

38. Park, H. J., Jeon, Y. K., You, D. H. & Nam, M. J. Daidzein causes cytochrome c-mediated apoptosis via the Bcl-2 family in human hepatic cancer cells. *Food Chem Toxicol*. 60, 542–549 (2013).

39. Chou, C.-C. *et al*. Quercetin-mediated cell cycle arrest and apoptosis inducing of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. *Arch Pharm Res*. 33, 1181–1191 (2010).

40. Gerasimenko, I. V. *et al*. Menadione-induced apoptosis: roles of cytosolic Ca2+ elevations and the mitochondrial permeability transition pore. *J Cell Sci*. 115, 485–497 (2002).

41. Schug, Z. T., Gonzalez, F., Houtkooper, R., Vaz, F. M. & Gottlieb, E. BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. *Cell Death Differ*. 18, 538–548 (2011).
44. Hajrezaie, M. et al. A Schiff Base-derived copper (II) complex is a potent inducer of apoptosis in colon cancer cells by activating the intrinsic pathway. *Scientific World J.*, doi: 10.1155/2014/540463 (2014).

45. Lee, J. S., Jung, W.-K., Jeong, M. H., Yoon, T. R. & Kim, H. K. Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway. *Int J Toxicol*. 31, 70–77 (2012).

46. Su, J. et al. Trichothecin induces cell death in NF-κB constitutively activated human cancer cells via inhibition of IKKβ phosphorylation. *Plos one*. 8, e71333 (2013).

47. Shakibaei, M. et al. Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways. *Plos one*. 8, e57218 (2013).

48. Rahman, H. S. et al. Zerumbone-loaded nanostructured lipid carrier induces G2/M cell cycle arrest and apoptosis via mitochondrial pathway in a human lymphoblastic leukemia cell line. *Int J Nanomedicine*. 9, 527 (2014).

49. Wang, X., Grunz-Borgmann, E. A. & Parrish, A. R. Loss of β-catenin potentiates cisplatin-induced nephrotoxicity via increasing apoptosis in renal tubular epithelial cells. *Toxicol Sci*. 1, 141 (2014).

50. OECD Guideline for testing of chemicals. Guidelines for the testing of chemicals and related documents. http://www.oecd.org/chemicalsafety/testing/oecdguidelinesforthetestingofchemicals.htm; Accessed: 2012 Nov 13 (2005).

51. Garber, J., Barbee, R. & Biehlitzki, J. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. *Guide for the Care and Use of Laboratory Animals*, 8th edition. Washington (DC): National Academies Press (US); (2011). Available from: http://www.ncbi.nlm.nih.gov/books/NBK54050/ (Date of Access: 11/01/2015).

52. Festing, M. F. W., et al. Reducing the use of laboratory animals in biomedical research: problems and possible solutions. *ATLA-NOTTINGHAM*. 26, 283–302 (1998).

Acknowledgements
The authors would like to express their ultimate appreciation and gratitude to University of Malaya and Ministry of Higher Education (HIR Grant H-20001-00-E00046) and Postgraduate Research Grant (PPP) PG021-2014B for supporting the current study. We also express our deepest appreciation to Nooshin Mohebali which helped us in this work.

Author Contributions
Conceived and designed the study: N.S., S.M., M.S.K. and B.S.H. Performed the experiments: N.S. Analyzed the data: N.S., S.M. and R.E.R.A. Contributed reagents/materials/analysis tools: B.S.H., S.M. and M.S.K. Wrote the manuscript: N.S. and B.S.H.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Samie, N. et al. Novel piperazine core compound induces death in human liver cancer cells: possible pharmacological properties. *Sci. Rep.* 6, 24172; doi: 10.1038/srep24172 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Retraction: Novel piperazine core compound induces death in human liver cancer cells: possible pharmacological properties

Nima Samie, Sekaran Muniandy, M. S. Kanthimathi, Batoul Sadat Haerian & Raja Elina Raja Azudin

Scientific Reports 6:24172; doi: 10.1038/srep24172; published online 13 April 2016; updated 22 June 2016

This Article has been retracted by the Editors and Publishers of Scientific Reports. Following online criticisms of the published paper, an investigation at the journal has confirmed the manipulation and duplication of data and a level of image processing that is not compliant with the journal's policies on image data integrity in figures 1–3, 6, 7, 10 and 12. Versions of figures 1–11 and large sections of the text had also previously been published1,2.

All authors acknowledge these issues and agree to the retraction of the Article.

References
1. Samie, N. et al. Mechanism of Action of the Novel Nickel(II) Complex in Simultaneous Reactivation of the Apoptotic Signaling Networks Against Human Colon Cancer Cells. Front. Pharmacol. 6, 313 (2016). doi: 10.3389/fphar.2015.00313
2. Samie, N., Muniandy, S., Kanthimathi, M. S. & Haerian, B. S. Mechanism of action of novel piperazine containing a toxicant against human liver cancer cells. PeerJ 4, e1588 (2016). doi: 10.7717/peerj.1588

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/